<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05796674</url>
  </required_header>
  <id_info>
    <org_study_id>ILS241-R001</org_study_id>
    <nct_id>NCT05796674</nct_id>
  </id_info>
  <brief_title>Clareon IOL Retrospective Data Collection</brief_title>
  <official_title>Post Market Clinical Follow-up (PMCF) Pilot Study for the Clareon UVA IOLs Using Retrospective Data Collection From the WaveTec AnalyzOR Database</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide real world evidence (RWE) on the performance of the&#xD;
      Clareon ultraviolet absorbing (UVA) intraocular lenses (IOLs) to support the overall body of&#xD;
      evidence on the Clareon IOL family.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this retrospective postmarket study, the WaveTec AnalyzOR Database will be reviewed. All&#xD;
      available data that meet the data selection criteria as of the data cutoff will be analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2023</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Monocular Best Corrected Distance Visual Acuity (BCDVA) at Postoperative Visit</measure>
    <time_frame>Month 1 postoperative</time_frame>
    <description>The database will be reviewed for assessments of monocular (by-eye) best corrected distance visual acuity at the first postoperative visit. The first postoperative visit will be defined as the visit which occurred approximately 28 days or later from the operative visit during which time the IOL remained implanted in the eye and an eye exam was performed.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Aphakia</condition>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>Clareon UVA IOL</arm_group_label>
    <description>Eyes that underwent cataract surgery and received a Clareon UVA IOL with the use of the WaveTec Optiwave Refractive Analysis (ORA) System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clareon UVA IOL</intervention_name>
    <description>Clareon UVA IOL placed in the capsular bag in the posterior chamber of the eye during cataract surgery to replace the natural crystalline lens. Models CC60WF and CCA0T0 are indicated for the visual correction of aphakia. Models CCW0T3, CCW0T4, CCW0T5, and CCW0T6 are indicated for the visual correction of aphakia and preexisting corneal astigmatism.</description>
    <arm_group_label>Clareon UVA IOL</arm_group_label>
    <other_name>Models CC60WF, CCW0T3, CCW0T4, CCW0T5, CCW0T6, CCA0T0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WaveTec Optiwave Refractive Analysis (ORA) System</intervention_name>
    <description>Intra-operative system used during refractive cataract surgery to capture wavefront images of the patient's eye for the purpose of optimizing IOL implantation</description>
    <arm_group_label>Clareon UVA IOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract surgery</intervention_name>
    <description>Cataract extraction by phacoemulsification, followed by implantation with a Clareon UVA IOL</description>
    <arm_group_label>Clareon UVA IOL</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A description of the population from which the groups or cohorts will be selected (for&#xD;
        example, primary care clinic, community sample, residents of a certain town).&#xD;
&#xD;
        Information is entered into the WaveTec AnalyzOR Database by medical professionals post&#xD;
        cataract surgery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Data Selection Criteria (eyes):&#xD;
&#xD;
          -  Must have undergone cataract extraction by phacoemulsification with implantation of a&#xD;
             Clareon UVA IOL (CC60WF, CCW0T3, CCW0T4, CCW0T5, CCW0T6, or CCA0T0) using the WaveTec&#xD;
             ORA System.&#xD;
&#xD;
          -  Must have a BCDVA in the WaveTec AnalyzOR Database from ≥ 10 days after surgery.&#xD;
&#xD;
          -  Predicted residual refractive error spherical equivalent (SE) ≤ 0.75 D.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Lead, Surgical</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alcon Call Center</last_name>
    <phone>1-888-451-3937</phone>
    <email>alcon.medinfo@alcon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alcon Research, LLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
    <mesh_term>Aphakia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

